Related references
Note: Only part of the references are listed.Altered Cytotoxicity Profile of CD8+T Cells in Ankylosing Spondylitis
Eric Gracey et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers
Kazushige Yoshida et al.
ONCOTARGETS AND THERAPY (2019)
The association of PD-L1 expression with the efficacy of antiPD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials
Yangyang Xu et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary roundtable discussion
Anna S. Berghoff et al.
ESMO OPEN (2019)
Influence of photodynamic therapy on peripheral immune cell populations and cytokine concentrations in head and neck cancer
M. N. Theodoraki et al.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY (2017)
Perforin-A key (shaped) weapon in the immunological arsenal
Bradley A. Spicer et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2017)
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
Petros Fessas et al.
SEMINARS IN ONCOLOGY (2017)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis
Omar Abdel-Rahman
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Luis Martinez-Lostao et al.
CLINICAL CANCER RESEARCH (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Evaluation of Serum Perforin, Caspase-3, sFasL and M-30 Levels as Apoptotic Markers in Children With Crimean-Congo Hemorrhagic Fever
Ahmet S. Guven et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2015)
Perforin and granzymes: function, dysfunction and human pathology
Ilia Voskoboinik et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Perforin: an important player in immune response
Iwona Osinska et al.
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells
G. Hodge et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8+ T cells and dendritic cells
Catherine E. Terrell et al.
BLOOD (2013)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study
Meisam Mahdavi et al.
HEPATITIS MONTHLY (2013)
Perforinopatly: a spectrum of human immune disease caused by defective perforin delivery or function
Ilia Voskoboinik et al.
FRONTIERS IN IMMUNOLOGY (2013)
Perforin deficiency and susceptibility to cancer
A. J. Brennan et al.
CELL DEATH AND DIFFERENTIATION (2010)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Elevated levels of serum perforin in chronic HIV-1 and acute SIV/SHIV infection
J Klingström et al.
AIDS (2006)
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
C Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Share Paper
